Literature DB >> 12163591

Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF.

Shih-Min Huang1, D J McCance.   

Abstract

Previously, we reported that human papillomavirus (HPV) type 16 E6 binds to C/H1, C/H3, and the C-terminal domains of coactivators p300 and CBP, causing the modulation of the transcription of certain genes controlled by NF-kappaB (p65 or relA) and p53. To establish the biological significance of these observations, we have focused on the transcriptional regulation of interleukin-8 (IL-8), a potent chemoattractant for T lymphocytes and neutrophils, which is also essential for the initiation of the local immune response. The IL-8 promoter is regulated by NF-kappaB/p65 in response to tumor necrosis factor alpha and requires the cooperation of the coactivators CBP/p300 and steroid receptor coactivator 1 (SRC-1) and the p300/CBP-associated factor (P/CAF) for optimal activation. Here we report that, in the presence of HPV-16 E6, the promoter activity of IL-8 was repressed. Moreover, from the mutational analysis of the IL-8 promoter, we found that E6 down-regulates the IL-8 promoter activity through the NF-kappaB/p65 binding site. This inhibition appears to result from the ability of HPV-16 E6 to compete with NF-kappaB/p65 and SRC-1 for binding to the N terminus and C terminus of CBP, respectively. Reporter data also showed that E7 represses IL-8 promoter activity, though to a lesser extent than E6 but, like E6, the repression by E7 is through the NF-kappaB/p65 binding site. E7 was shown for the first time to bind to P/CAF, and the binding was necessary for the down regulation of the IL-8 promoter. E6 and E7 together inhibited transcription of the IL-8 promoter to a greater extent than either alone. Finally, by RNase protection assay, we showed that the synthesis of endogenous IL-8 mRNA was repressed in keratinocytes stably expressing E6 and E7. Taken together, the results provide evidence that E6 and E7 can cooperatively disrupt IL-8 transcription through disruption of transcriptional active complexes, and this may have important consequences for immune responses in infected hosts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163591      PMCID: PMC136974          DOI: 10.1128/jvi.76.17.8710-8721.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Transcriptional activation by NF-kappaB requires multiple coactivators.

Authors:  K A Sheppard; D W Rose; Z K Haque; R Kurokawa; E McInerney; S Westin; D Thanos; M G Rosenfeld; C K Glass; T Collins
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

Authors:  A S Neish; A T Gewirtz; H Zeng; A N Young; M E Hobert; V Karmali; A S Rao; J L Madara
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

3.  Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.

Authors:  R Eckner; T P Yao; E Oldread; D M Livingston
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

4.  Detection of cellular proteins associated with human adenovirus type 5 early region 1A polypeptides.

Authors:  S P Yee; P E Branton
Journal:  Virology       Date:  1985-11       Impact factor: 3.616

5.  Induction of RANTES chemokine expression in human astrocytic cells is dependent upon activation of NF-kappaB transcription factor.

Authors:  Q Q Li; C T Bever; D R Burt; S I Judge; G D Trisler
Journal:  Int J Mol Med       Date:  2001-05       Impact factor: 4.101

6.  Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.

Authors:  A H Lee; J H Hong; Y S Seo
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

7.  Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines.

Authors:  C D Woodworth; S Simpson
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

9.  Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Authors:  P S Huang; D R Patrick; G Edwards; P J Goodhart; H E Huber; L Miles; V M Garsky; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

10.  The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation.

Authors:  M S Barbosa; C Edmonds; C Fisher; J T Schiller; D R Lowy; K H Vousden
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

View more
  62 in total

Review 1.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

3.  Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization.

Authors:  Erik R Vandermark; Krysta A Deluca; Courtney R Gardner; Daniel F Marker; Cynthia N Schreiner; David A Strickland; Katelynn M Wilton; Sumona Mondal; Craig D Woodworth
Journal:  Virology       Date:  2012-01-28       Impact factor: 3.616

4.  The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms.

Authors:  Andreas Müller-Schiffmann; Julia Beckmann; Gertrud Steger
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Steroid receptor coactivators as therapeutic targets in the female reproductive system.

Authors:  Maria M Szwarc; John P Lydon; Bert W O'Malley
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-04       Impact factor: 4.292

6.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

Review 7.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Progesterone and the Repression of Myometrial Inflammation: The Roles of MKP-1 and the AP-1 System.

Authors:  K Lei; E X Georgiou; L Chen; A Yulia; S R Sooranna; J J Brosens; P R Bennett; M R Johnson
Journal:  Mol Endocrinol       Date:  2015-08-17

9.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

10.  Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites.

Authors:  Sohrab Bodaghi; Rong Jia; Zhi-Ming Zheng
Journal:  Virology       Date:  2009-02-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.